C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	20.76	31.1	45.79	33.2	21.38
Revenue Growth (YoY)	-33.25%	-32.08%	37.93%	55.25%	10.42%
Gross Profit	20.76	31.1	45.79	33.2	21.38
Selling, General & Admin	42.08	42.79	33.25	15.2	8.77
Research & Development	117.71	117.84	94.67	78.44	48.06
Operating Expenses	159.79	160.63	127.92	93.64	56.83
Operating Income	-139.03	-129.53	-82.13	-60.45	-35.45
Interest Expense / Income	1.37	2.22	2.15	1.23	0
Other Expense / Income	-9.19	-3.58	-0.39	5.28	-2.16
Pretax Income	-131.21	-128.18	-83.89	-66.96	-33.3
Income Tax	1.28	0	0	-0.63	0.8
Net Income	-132.49	-128.18	-83.89	-66.34	-34.1
Preferred Dividends	0	0	0	0	8.47
Net Income Common	-132.49	-128.18	-83.89	-66.34	-42.57
Shares Outstanding (Basic)	50	49	46	11	1
Shares Outstanding (Diluted)	50	49	46	11	1
Shares Change	1.59%	6.12%	304.93%	728.80%	-87.42%
EPS (Basic)	-2.67	-2.62	-1.82	-5.83	-31.03
EPS (Diluted)	-2.67	-2.62	-1.82	-5.83	-31.03
Free Cash Flow	-108.55	-111.44	-88.24	-67.9	54.33
Free Cash Flow Per Share	-2.19	-2.28	-1.92	-5.97	39.60
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-669.84%	-416.56%	-179.39%	-182.10%	-165.81%
Profit Margin	-638.34%	-412.19%	-183.23%	-199.83%	-199.09%
Free Cash Flow Margin	-522.96%	-358.36%	-192.73%	-204.55%	254.09%
EBITDA	-121.8	-118.39	-78.84	-62.89	-30.56
EBITDA Margin	-586.82%	-380.71%	-172.20%	-189.46%	-142.91%
Depreciation & Amortization	8.04	7.57	2.91	2.84	2.74
EBIT	-129.84	-125.96	-81.75	-65.73	-33.3
EBIT Margin	-625.55%	-405.06%	-178.55%	-198.02%	-155.72%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).